F10 and Stroke: A subanalysis of the “Rivaroxaban Once daily oral direct factor Xa inhibition compared with VKA for prevention of stroke and Embolism Trial in AF” (ROCKET AF) also found that anticoagulated patients with persistent AF (11,548 patients) were at higher risk of stroke versus those with PAF (2,514 patients)33.